Artesunate, an antimalarial drug, has been shown to inhibit the release of inflammatory mediators in various disease conditions. The present study was carried out to evaluate the anti-edematogenic effect of arte- suna...Artesunate, an antimalarial drug, has been shown to inhibit the release of inflammatory mediators in various disease conditions. The present study was carried out to evaluate the anti-edematogenic effect of arte- sunate in the rat paw edema model. Inflammation was induced in the hind paw of rat by sub-plantar injection of 0.1 mL of 0.5% carrageenan and the paw volume was measured up to a fixed mark just before the injection and then after 3 h. The difference in two volumes gave a measure of edema formation. At 3h the level of TNF-α, PGE_(2) and myeloperoxidase were estimated in the inflamed paw tissue. Treatment of rats with single dose of artesunate at 50 and 150 mg/kg produced a dose-dependent inhibition in paw inflammation where a significant reduction in edema volume and mediator release was observed. Our study shows that by inhibiting the release of inflam- matory mediators artesunate affords protection against acute inflammation induced in the rat paw and suggests that it has a potential to be used in the treatment of inflammatory disease conditions.展开更多
Background:Helicobacter pylori infection has been associated with insulin resistance and non-alcoholic fatty liver disease(NAFLD).This study was done to evaluate the effect of H.pylori-eradication therapy(HPET)in pati...Background:Helicobacter pylori infection has been associated with insulin resistance and non-alcoholic fatty liver disease(NAFLD).This study was done to evaluate the effect of H.pylori-eradication therapy(HPET)in patients with NAFLD compared to standard management therapy(SMT).Methods:Eighty NAFLD patients with H.pylori co-infection were randomized into SMT(diet and exercise,n=36)and HPET(SMT plus amoxicillin,clarithromycin,and pantoprazole,n=44)groups.The controlled attenuation parameter(CAP),anthropometric parameters,liver enzymes,lipid profile,and glycemic parameters including homeostasis model assessment-insulin resistance(HOMA-IR)were measured and compared between two groups at the baseline and 24 weeks.Results:Sixty-four participants(SMT group[n=28]and HPET group[n=36])were included in amodified intention-to-treat analysis.Both the SMT group and the HPET group had a significant reduction in CAP scores at 24weeks(P=0.002 and P<0.001,respectively),but the change between the groups was insignificant(P=0.213).Successful eradication of H.pylori occurred in 68%of the HPET group and led to greater improvement in HOMA-IR at 24weeks compared to SMT or non-responder patients(P=0.007).The liver enzymes reduced significantly at 24weeks in both groups,but the changes between the groups were similar.The lipid parameters remained unchanged within the groups and between the groups at 24weeks.A significant increase in the levels of reduced glutathione was noted in the HPET group,but the change between the two groups was not statistically different.Conclusions:HPET was found to be comparable to SMT alone in reducing hepatic steatosis and liver enzymes at 24 weeks in NAFLD patients.However,successful eradication of H.pylori led to greater improvement in HOMA-IR(Trial registration CTRI/2017/05/008608).展开更多
基金research grant(A-059)from All India Institute of Medical Sciences,New Delhi.Artesunate and diclofenac were kind gifts from Arbro Pharmaceuticals Ltd.,New Delhi.
文摘Artesunate, an antimalarial drug, has been shown to inhibit the release of inflammatory mediators in various disease conditions. The present study was carried out to evaluate the anti-edematogenic effect of arte- sunate in the rat paw edema model. Inflammation was induced in the hind paw of rat by sub-plantar injection of 0.1 mL of 0.5% carrageenan and the paw volume was measured up to a fixed mark just before the injection and then after 3 h. The difference in two volumes gave a measure of edema formation. At 3h the level of TNF-α, PGE_(2) and myeloperoxidase were estimated in the inflamed paw tissue. Treatment of rats with single dose of artesunate at 50 and 150 mg/kg produced a dose-dependent inhibition in paw inflammation where a significant reduction in edema volume and mediator release was observed. Our study shows that by inhibiting the release of inflam- matory mediators artesunate affords protection against acute inflammation induced in the rat paw and suggests that it has a potential to be used in the treatment of inflammatory disease conditions.
基金AIIMS Intramural grant[No.F.8-539/A-539/2017/RS]AIIMS Ethical committee No.IEC-236/05.05.2017,RP-25/2017,dated 25 May 2017.
文摘Background:Helicobacter pylori infection has been associated with insulin resistance and non-alcoholic fatty liver disease(NAFLD).This study was done to evaluate the effect of H.pylori-eradication therapy(HPET)in patients with NAFLD compared to standard management therapy(SMT).Methods:Eighty NAFLD patients with H.pylori co-infection were randomized into SMT(diet and exercise,n=36)and HPET(SMT plus amoxicillin,clarithromycin,and pantoprazole,n=44)groups.The controlled attenuation parameter(CAP),anthropometric parameters,liver enzymes,lipid profile,and glycemic parameters including homeostasis model assessment-insulin resistance(HOMA-IR)were measured and compared between two groups at the baseline and 24 weeks.Results:Sixty-four participants(SMT group[n=28]and HPET group[n=36])were included in amodified intention-to-treat analysis.Both the SMT group and the HPET group had a significant reduction in CAP scores at 24weeks(P=0.002 and P<0.001,respectively),but the change between the groups was insignificant(P=0.213).Successful eradication of H.pylori occurred in 68%of the HPET group and led to greater improvement in HOMA-IR at 24weeks compared to SMT or non-responder patients(P=0.007).The liver enzymes reduced significantly at 24weeks in both groups,but the changes between the groups were similar.The lipid parameters remained unchanged within the groups and between the groups at 24weeks.A significant increase in the levels of reduced glutathione was noted in the HPET group,but the change between the two groups was not statistically different.Conclusions:HPET was found to be comparable to SMT alone in reducing hepatic steatosis and liver enzymes at 24 weeks in NAFLD patients.However,successful eradication of H.pylori led to greater improvement in HOMA-IR(Trial registration CTRI/2017/05/008608).
